Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Eunice L. Lozada-Delgado"'
Autor:
Nilmary Grafals-Ruiz, Annelis O. Sánchez-Álvarez, Yasmarie Santana-Rivera, Eunice L. Lozada-Delgado, Robert J. Rabelo-Fernandez, Christian I. Rios-Vicil, Fatima Valiyeva, Pablo E. Vivas-Mejia
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionGlioblastoma (GBM) is a highly aggressive and lethal primary brain tumor. Despite limited treatment options, the overall survival of GBM patients has shown minimal improvement over the past two decades. Factors such as delayed cancer diag
Externí odkaz:
https://doaj.org/article/729159b29ebf449a8320808f42799637
Autor:
Gabriel Martínez-Zayas, Ginette S Santiago-Sánchez, Fatma Valiyeva, Yasmarie Santana-Rivera, Eunice L Lozada-Delgado, Pablo E. Vivas-Mejia, Ricardo A Noriega-Rivera, Nilmary Grafals-Ruiz, Blanca I Quiñones-Díaz, Christian I. Ríos-Vicil
Publikováno v:
International Journal of Nanomedicine. 15:2809-2828
Introduction Glioblastoma (GBM) is the most common and lethal of the central nervous system (CNS) malignancies. The initiation, progression, and infiltration ability of GBMs are attributed in part to the dysregulation of microRNAs (miRNAs). Thus, tar
Autor:
Nilmary, Grafals-Ruiz, Christian I, Rios-Vicil, Eunice L, Lozada-Delgado, Blanca I, Quiñones-Díaz, Ricardo A, Noriega-Rivera, Gabriel, Martínez-Zayas, Yasmarie, Santana-Rivera, Ginette S, Santiago-Sánchez, Fatma, Valiyeva, Pablo E, Vivas-Mejía
Publikováno v:
International Journal of Nanomedicine
Introduction Glioblastoma (GBM) is the most common and lethal of the central nervous system (CNS) malignancies. The initiation, progression, and infiltration ability of GBMs are attributed in part to the dysregulation of microRNAs (miRNAs). Thus, tar
Autor:
Nilmary Grafals-Ruiz, Pablo E. Vivas-Mejia, Mónica Rivera-Díaz, Yasmarie Santana-Rivera, Fatma Valiyeva, Eunice L Lozada-Delgado
Publikováno v:
The FASEB Journal. 33
Autor:
Nilmary Grafals-Ruiz, Yasmarie Santana-Rivera, Eunice L Lozada-Delgado, Mónica Rivera-Díaz, María J. Marcos-Martínez, Fatma Valiyeva, Pablo E. Vivas-Mejia, Miguel A Miranda-Román
Publikováno v:
Cancers, Vol 10, Iss 10, p 382 (2018)
Cancers
Volume 10
Issue 10
Cancers
Volume 10
Issue 10
Glioblastoma (GBM) is the most common and aggressive of all brain tumors, with a median survival of only 14 months after initial diagnosis. Novel therapeutic approaches are an unmet need for GBM treatment. MicroRNAs (miRNAs) are a class of small non-
Autor:
Edgardo Santiago-Rivera, Lymarie M. Díaz-Díaz, Kelvin Carrasquillo-Carrión, Adriana Rivera-Dompenciel, Eunice L Lozada-Delgado, A. Valance Washington, Juan C. Villalobos-Santos, Javier Menéndez-Pérez, Abiel Roche-Lima, Jessica Morales-Ortíz, Barbara Manfredi, J Alejandro Rodríguez-Cordero, Delmaliz Barreto-Vázquez, Liz Hernandez-Matias, Madhavi Kuchibhotla
Publikováno v:
Monoclonal antibodies in immunodiagnosis and immunotherapy. 37(2)
Platelets play a vital role in hemostasis and inflammation. The membrane receptor TREM-like transcript-1 (TLT-1) is involved in platelet aggregation, bleeding, and inflammation, and it is localized in the α-granules of platelets. Upon platelet activ
Glioblastoma multiforme (GBM) is the most common and deadliest type of primary brain tumor with a prognosis of 14 months after diagnosis. Current treatment for GBM patients includes “total” tumor resection, temozolomide-based chemotherapy, radiot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adac825d70c71edaa710ea5839ea896c
https://europepmc.org/articles/PMC5617340/
https://europepmc.org/articles/PMC5617340/
Publikováno v:
Cancer Research. 78:527-527
The purpose of this study is to assess the biological role of microRNA-143 (miR-143) in Glioblastoma multiforme (GBM). In the United States, the incidence of GBM is about 17% of all primary brain tumors and about 60-75% of all Astrocytomas. Many pati
Publikováno v:
Cancer Research. 77:3437-3437
The purpose of this study is to assess the biological role of the microRNA-143 (miR-143) in Glioblastoma multiforme (GBM). GBM is the most common and lethal of all brain tumors. In the United States, the incidence of GBM is about 17% of all primary b